1. OPUS at UTS

Browsing byAuthorHardy, J

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 25 to 40 of 40< previous 
Issue DateTitleAuthor(s)
2019-12-06Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: A double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD)Good, P; Haywood, A; Gogna, G; Martin, J; Yates, P; Greer, R; Hardy, J
2020-07-06Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).Hardy, J; Haywood, A; Gogna, G; Martin, J; Yates, P; Greer, R; Good, P
2010-02-01Patient care guidelines: A telephone survey of intensive care practices in New South WalesKnowles, S; Rolls, K; Elliott, D; Hardy, J; Middleton, S
2023-03-01Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD).Hardy, J; Greer, R; Huggett, G; Kearney, A; Gurgenci, T; Good, P
2013-11-01Placebo and nocebo effects in randomized controlled trials: The implications for research and practiceSanderson, C; Hardy, J; Spruyt, O; Currow, DC
2021-03Practice review: Evidence-based quality use of corticosteroids in the palliative care of patients with advanced cancer.Hardy, J; Haywood, A; Rickett, K; Sallnow, L; Good, P
2014-04-15Preliminary development and validation of a new endof-life patient-reported outcome measure assessing the ability of patients to finalise their affairs at the end of lifeMcCaffrey, N; Skuza, P; Breaden, K; Eckermann, S; Hardy, J; Oaten, S; Briffa, M; Currow, D
2016Quantitative determination of the enantiomers of methadone in human plasma and saliva by chiral column chromatography coupled with mass spectrometric detection.George, R; Lobb, M; Haywood, A; Khan, S; Hardy, J; Good, P; Hennig, S; Norris, R
2018-05-02A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatmentHardy, J; Skerman, H; Glare, P; Philip, J; Hudson, P; Mitchell, G; Martin, P; Spruyt, O; Currow, D; Yates, P
2012-10-10Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer painHardy, J; Quinn, S; Fazekas, B; Plummer, J; Eckermann, S; Agar, M; Spruyt, O; Rowett, D; Currow, DC
2022-06-14Research agenda for medical cannabis in palliative care.Gurgenci, T; Hardy, J; Good, P
2012-09-01Sector-wide approach to phase III studiesHardy, J; Currow, DC
2016-09-01Single-patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: A pilot studyNikles, J; Mitchell, GK; Hardy, J; Senior, H; Carmont, SA; Schluter, PJ; Vora, R; Currow, D; Yelland, M
2022-01-01Survival following palliative percutaneous nephrostomy tube insertion in patients with malignant ureteric obstruction: Validating a prognostic modelGunawan, B; Foster, K; Hardy, J; Good, P
2022-09-05Using a qualitative sub-study to inform the design and delivery of randomised controlled trials on medicinal cannabis for symptom relief in patients with advanced cancer.Olson, RE; Smith, A; Huggett, G; Good, P; Dudley, M; Hardy, J
2023-02'What price do you put on your health?': Medical cannabis, financial toxicity and patient perspectives on medication access in advanced cancer.Olson, RE; Smith, A; Good, P; Dudley, M; Gurgenci, T; Hardy, J
Showing results 25 to 40 of 40< previous